Drug WatchDrug Receives New Indication for Pediatric Graft-Versus-Host DiseaseAschenbrenner, Diane S. MS, RN Author Information Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch: [email protected]. AJN, American Journal of Nursing 122(12):p 23, December 2022. | DOI: 10.1097/01.NAJ.0000904084.55613.b6 Buy Metrics Abstract Ibrutinib (Imbruvica) has received a new indication for the treatment of graft-versus-host disease in pediatric patients at least one year of age when one or more systemic therapies have failed. The product's labeling warns of the risk of hemorrhage, infections, cardiac arrythmias, cardiac failure and sudden death, hypertension, cytopenia, secondary primary malignancies, tumor lysis syndrome, and embryo–fetal toxicity. The most common adverse effects include laboratory abnormalities, musculoskeletal pain, pyrexia, pneumonia, abdominal pain, stomatitis, diarrhea, and headache. Nurses should carefully assess for these adverse effects and provide appropriate education regarding their prevention. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.